# Clinical Studies Core

> **NIH NIH U54** · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2020 · $81,242,031

## Abstract

RESEARCH SUMMARY/ABSTRACT
The goal of this initiative is to fast-track the implementation of carefully selected CAPCaT-supported
projects that can help address the urgent healthcare issues created by the COVID-19 pandemic. The
extent and urgency of the situation requires an aggressive approach to accelerate the delivery of solutions to
address the immediate needs. The proposed approach augments the strong technical, clinical and
commercialization expertise of CAPCaT to get needed solutions into practice within weeks to months.
The Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep
Diseases is an offshoot of a highly successful medical product incubator, the Massachusetts Medical Device
Development Center (M2D2) at the University of Massachusetts Lowell and Medical School campuses. The
founding goal of M2D2 was to accelerate the development of medical devices, combining the engineering and
business expertise of UMass Lowell (UML) with the clinical expertise of UMass Medical School (UMMS) in
Worcester. Expanding upon the vision and success of M2D2, the goal of CAPCaT is to support projects to
develop and optimize novel point of care technologies (POCT) to improve the diagnosis and management of
heart, lung, blood, and sleep diseases. We have focused on these diseases because of the significant
morbidity, mortality, and cost associated with these diseases. Combined, these diseases account for 41% of
deaths in the US and lead to over $400B in direct health care expenses plus lost income to affected patients
and caregivers. UMass has an established track record of clinical expertise and technology development in the
HLBS diseases. CAPCaT funds projects that are in the later stages of POCT development, with a focus on the
clinical validation of those devices. CAPCaT, along with M2D2, has a network of industry partners and funders
to support the development and commercialization of promising technologies. Among our industry partners are
Johnson & Johnson, Boston Scientific, Amgen, and Hologic.
CAPCaT is one of four Point of Care Technology Research Network (POCTRN) Centers (Emory/GA Tech,
Northwestern, and Johns Hopkins University house the others). CAPCaT has worked with the other POCTRN
Centers and its Coordinating Center (CIMIT-Mass General Hospital) and our scientific and program officers at
NHLBI and NIBIB to review the situation and to understand unmet needs and resources accessible by the
network that can make a difference.

## Key facts

- **NIH application ID:** 10204697
- **Project number:** 3U54HL143541-02S2
- **Recipient organization:** UNIV OF MASSACHUSETTS MED SCH WORCESTER
- **Principal Investigator:** BRYAN O BUCHHOLZ
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $81,242,031
- **Award type:** 3
- **Project period:** 2020-07-17 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10204697

## Citation

> US National Institutes of Health, RePORTER application 10204697, Clinical Studies Core (3U54HL143541-02S2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10204697. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*